Cetuximab in metastatic colorectal cancer

V Broadbridge; Christos Karapetis; Timothy Price

doi:10.1586/era.12.25

Cetuximab in metastatic colorectal cancer

V Broadbridge, Christos Karapetis, Timothy Price

Research output: Contribution to journal › Review article › peer-review

31 Citations (Scopus)

Abstract

Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.

Original language	English
Pages (from-to)	555-565
Number of pages	11
Journal	Expert Review of Anticancer Therapy
Volume	12
Issue number	5
DOIs	https://doi.org/10.1586/era.12.25
Publication status	Published - May 2012

Keywords

cetuximab
EGF receptor inhibitors
metastatic colorectal cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/era.12.25

Cite this

@article{dca0ac9acf374358b5b106c5040f5074,

title = "Cetuximab in metastatic colorectal cancer",

abstract = "Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.",

keywords = "cetuximab, EGF receptor inhibitors, metastatic colorectal cancer",

author = "V Broadbridge and Christos Karapetis and Timothy Price",

year = "2012",

month = may,

doi = "10.1586/era.12.25",

language = "English",

volume = "12",

pages = "555--565",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Cetuximab in metastatic colorectal cancer

AU - Broadbridge, V

AU - Karapetis, Christos

AU - Price, Timothy

PY - 2012/5

Y1 - 2012/5

N2 - Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.

AB - Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.

KW - cetuximab

KW - EGF receptor inhibitors

KW - metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84861325349&partnerID=8YFLogxK

U2 - 10.1586/era.12.25

DO - 10.1586/era.12.25

M3 - Review article

SN - 1473-7140

VL - 12

SP - 555

EP - 565

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -

Cetuximab in metastatic colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this